Showing results (201-210 of 210) with videos related to
Sort By:
Pageof 21
You have reached the last page of results.This site can display upto 210 results.
Cancer Immunology, Immunotherapy : CII|March 8, 2025
Effectiveness, safety, and patterns of use of camrelizumab in advanced esophageal cancer: an individual patient data pooled analysis of 987 patients from three prospective cohort studiesZhihao Lu, Guoping Sun, Jiancheng Li, et al.Med (New York, N.Y.)|July 10, 2024
A randomized phase 2 study of HLX22 plus trastuzumab biosimilar HLX02 and XELOX as first-line therapy for HER2-positive advanced gastric cancerNing Li, Meng Qiu, Yanqiao Zhang, et al.Cancer Medicine|May 23, 2020
Effectiveness and safety of low-dose apatinib in advanced gastric cancer: A real-world studyYingying Du, Qisheng Cao, Congqiao Jiang, et al.Cancer Management and Research|August 22, 2020
Large Scale, Multicenter, Prospective Study of Apatinib in Advanced Gastric Cancer: A Real-World Study from ChinaWanren Peng, Fenglin Zhang, Zishu Wang, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2016
Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal JunctionJin Li, Shukui Qin, Jianming Xu, et al.Molecular Biology and Evolution|March 20, 2024
Ancient Mitogenomes Reveal the Maternal Genetic History of East Asian DogsMing Zhang, Yanbo Song, Caihui Wang, et al.Lung Cancer (Amsterdam, Netherlands)|August 1, 2024
Befotertinib for patients with pretreated EGFR T790M mutated locally advanced or metastatic NSCLC: Final overall survival results from a phase 2 trialShun Lu, Yiping Zhang, Guojun Zhang, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 20, 2022
Efficacy and Safety of Befotertinib (D-0316) in Patients With EGFR T790M-Mutated NSCLC That Had Progressed After Prior EGFR Tyrosine Kinase Inhibitor Therapy: A Phase 2, Multicenter, Single-Arm, Open-Label StudyShun Lu, Yiping Zhang, Guojun Zhang, et al.Lancet (London, England)|October 19, 2024
Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in ChinaXiaohua Wu, Yang Sun, Hongying Yang, et al.Nature Communications|March 14, 2026
Cadonilimab plus chemotherapy with or without bevacizumab as first-line treatment for advanced cervical cancer: subgroup analyses from the COMPASSION-16 phase 3 trialYang Sun, Hongying Yang, Jing Wang, et al.Pageof 21